Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review

Phung, Cao Dai; Tran, Tuan Hiep; Kim, Jong Oh

doi:10.1007/s12272-020-01218-1

Cited by 25 publications

(15 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the sequential drug resistance has still been inevitable. Therefore, various studies have attempted to elucidate the mechanisms of resistance to overcome or delay the resistance of NSCLC cells (22,23,25,(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45). In addition, recent comprehensive proteomic technologies display a great opportunity to investigate novel clinically relevant oncogenic pathways that may have been over-looked by cancer gene screens (46,47).…”

Section: Discussionmentioning

confidence: 99%

Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers

et al. 2020

View full text Add to dashboard Cite

Background/Aim: The resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib or erlotinib, is considered a major challenge in the treatment of patients with non-small cell lung cancer (NSCLC). Herein, we identified the critical roles of anterior gradient 2 (AGR2) in gefitinib (Gef) resistance of mutant NSCLC cells. Materials and Methods: Using datasets from a pair of NSCLCsensitive and NSCLC-resistant cells, immunoblotting, immunofluorescence and immunohistochemistry, and cell viability assays were applied to identify the effects of AGR2. Results: AGR2 was found to be significantly over-expressed in Gef-resistant cells and was highly associated with drug resistance, proliferation, migration, and invasion of cancer cells. Moreover, AGR2 and ADAMTS6 formed a negative feedback loop in drug-resistant cells. Conclusion: Modulation of overexpression of AGR2 in mutant NSCLC cells may be an attractive therapeutic strategy for the treatment of EGFR-TKI-resistant NSCLC. Non-small cell lung cancer (NSCLC) is one of the major causes of cancer-related death worldwide, and comprises 85% of all lung cancer cases (1). Acquired drug resistance in tumor cells is a major obstacle in the field of anti-cancer chemotherapies. Likewise, NSCLC patients who initially show a good response to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib (Gef), acquire resistance to treatment (2). However, studies on the mechanisms through which overexpression of specific genes is involved in EGFR-TKI resistanse of NSCLC cells are scarce and its role remains to be elucidated. Therefore, novel approaches are required to elucidate their role in drug resistanse of cancer cells. The anterior gradient-2 (AGR2) has been identified in Xenopus laevis and plays a critical role in cemet gland differentiation (3). Recent studies have suggested that elevated expression of AGR2 is correlated with cell proliferation, metastasis, and drug resistance in various human cancer cell lines, such as prostate (4), breast (5), and pancreatic cancer (6). Moreover, overexpression of AGR2 has been notably correlated with a poor outcome of estrogen receptor-negative breast cancer patients (7). AGR2 is also a pro-oncogenic protein that has been shown to stimulate the epidermal growth factor receptor (EGFR) ligand amphiregulin, regulate p53 signaling, and interact with the AAA+ protein Reptin (8), suggesting its modulatory roles in gene expression. High expression of AGR2 has also been shown to be predictive of poor survival in lung cancer (9). However, there is still a lack of insightful understanding of the role of AGR2 in EGFR-TKI-resistant NSCLC cells. There are 19 members of zinc-dependent metalloproteases in the family of a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS) (10). Recent reports suggest the critical roles of ADAMTSs in angiogenesis and cancer (11). They also play an important role in the modulation of extracellular matrix. For instance, ADAMTS-1 metallopro...

show abstract

Section: Discussionmentioning

confidence: 99%

Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Considering the unique advantages of nanoparticle delivery technology for cancer immunotherapy, it can be exploited to develop therapeutic strategies to overcome the immune suppression from the TME of solid tumors and boost the antitumor function of NK cells (Table 2). 195,196 In order to increase NK cells recruitment and infiltration into the tumor site, NK cells were loaded onto magnetic nanoparticles comprising an Fe 3 O 4 core and polydopamine layer ex vivo and then injected into animals. Results showed this strategy can improve accumulation and retention of NK cells in tumors, resulting in significantly enhanced therapeutic efficacy.…”

Section: Nanoparticles For Modulating Nk Cellsmentioning

confidence: 99%

Targeting the innate immune system with nanoparticles for cancer immunotherapy

Zhang

et al. 2022

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Recently, various multifunctional nanoparticles have been suggested to augment NK cell therapy for the treatment of cancers [32,33]. Active molecules/cytokine delivery, imaging, and physicochemical properties of nanomaterials are well equipped to overcome NK cell cancer immunotherapy challenges [34,35]. As maturing nanotechnology and nanomedicine for the clinical applications, there is greater opportunity for NK cell cancer immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles

Kim

2021

Pharmaceutics

View full text Add to dashboard Cite

Among various immunotherapies, natural killer (NK) cell cancer immunotherapy using adoptive transfer of NK cells takes a unique position by targeting tumor cells that evade the host immune surveillance. As the first-line innate effector cell, it has been revealed that NK cells have distinct mechanisms to both eliminate cancer cells directly and amplify the anticancer immune system. Over the last 40 years, NK cell cancer immunotherapy has shown encouraging reports in pre-clinic and clinic settings. In total, 288 clinical trials are investigating various NK cell immunotherapies to treat hematologic and solid malignancies in 2021. However, the clinical outcomes are unsatisfying, with remained challenges. The major limitation is attributed to the immune-suppressive tumor microenvironment (TME), low activity of NK cells, inadequate homing of NK cells, and limited contact frequency of NK cells with tumor cells. Innovative strategies to promote the cytolytic activity, durable persistence, activation, and tumor-infiltration of NK cells are required to advance NK cell cancer immunotherapy. As maturing nanotechnology and nanomedicine for clinical applications, there is a greater opportunity to augment NK cell therapeutic efficacy for the treatment of cancers. Active molecules/cytokine delivery, imaging, and physicochemical properties of nanoparticles are well equipped to overcome the challenges of NK cell cancer immunotherapy. Here, we discuss recent clinical trials of NK cell cancer immunotherapy, NK cell cancer immunotherapy challenges, and advances of nanoparticle-mediated NK cell therapeutic efficacy augmentation.

show abstract

Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review

Cited by 25 publications

References 108 publications

Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers

Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers

Targeting the innate immune system with nanoparticles for cancer immunotherapy

Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles

Contact Info

Product

Resources

About